05.06.15
Catalent
3Q Revenues: $446.6 million (+8%)
3Q Earnings: $31.5 million (earnings were $6.7 million 3Q14)
YTD Revenues: $1.3 billion (+1%)
YTD Earnings: $58.5 million (loss of $11.0 million YTD14)
Comments: Growth was driven by the Oral Technologies segment ($284.0 million, +10% at constant currency) and increased demand for analytical services integrated operations within its Development and Clinical Services segment with $103.7 million for the quarter, up 4% at constant currency. Revenue from the Medication Delivery Solutions segment was $61.2 million, up 2% at constant currency. In the quarter, the company acquired Pharmapak Technologies, and completed a large-scale expansion at the Winchester, KY manufacturing facility.
3Q Revenues: $446.6 million (+8%)
3Q Earnings: $31.5 million (earnings were $6.7 million 3Q14)
YTD Revenues: $1.3 billion (+1%)
YTD Earnings: $58.5 million (loss of $11.0 million YTD14)
Comments: Growth was driven by the Oral Technologies segment ($284.0 million, +10% at constant currency) and increased demand for analytical services integrated operations within its Development and Clinical Services segment with $103.7 million for the quarter, up 4% at constant currency. Revenue from the Medication Delivery Solutions segment was $61.2 million, up 2% at constant currency. In the quarter, the company acquired Pharmapak Technologies, and completed a large-scale expansion at the Winchester, KY manufacturing facility.